2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5692 Engineering immunocompetent human in vitro multiple myeloma bone marrow model for disease modeling and therapy screening

Mikayla Ann Ybarra, BS, Jaehun Lee, PhD2, Habiba Shamroukh3, Chao Ma, PhD4
1 Case Western School-Medicine, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Case Western School-Medicine, Cleveland, Ohio, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States

Adoptive anti-BCMA chimeric antigen receptor (CAR) T-cell therapy shows promise in refractory/relapsed multiple myeloma (r/r‑MM) but relapse and resistance remain problematic. Two dimensional and current animal models fail to recapitulate the full human, immunocompetent BM microenvironment. To address these limitations, we built a human immunocompetent MM BM organ-on-a-chip model (M2BM) that reproduces organotypic structure/function to define molecular and cellular determinants of CAR T failure. The microfluidic organ-on-a-chip device was fabricated with specialized chambers to replicate the organization in bone marrow. Endosteal chambers were seeded with fibroblasts/osteoblasts, the medullary cavity loaded with hematopoietic stem cells (HSCs), human umbilical vein endothelial cells (HUVECs), mesenchymal stem cells (MSCs), and NCI H929 MM cells embedded in a fibrin hydrogel. Cellular composition was mapped by immunostaining (e.g. BCMA, CD90, CD31) and fluorescence imaging. Single cell RNA sequencing (scRNA‑seq) from nine MM patient BMs was used for cross-validation of cellular composition. After 7 days of culture, anti‑BCMA CAR T‑cells were added on-chip; where CAR T cytokine secretion was monitored by ELISA for IFN‑γ, perforin, granzyme‑B and T-cell activation confirmed using immunostaining and time lapse imaging. The device’s cellular ecosystem closely matched patient BM (R = 0.67). Compared with a non-diseased BM chip, differential expressed gene analysis of plasma cells revealed osteopontin (SPP1) to be highly expressed. Through additional ligand receptor pair analysis with CellChat, our findings suggest that myeloma may alter the immune cell ecosystem through the SPP1-CD44 axis which may contribute to poor therapeutic response in patients. SPP1 expression in MM cells was cross validated in newly diagnosed myeloma patient samples with the Multiple Myeloma Research Foundation Single Cell Atlas. We have also established successful T-cell infiltration and observed CAR‑T-mediated MM killing in the device. CAR‑T cells successfully depleted MM, with IFN‑γ, perforin and granzyme B cytokines peaking ~day 5 during 10-day monitoring. Time lapse imaging and immunofluorescence imaging confirmed the attenuation of MM in the M2BM device.

Mikayla Ann Ybarra, BS: No relevant conflicts of interest to declare.